Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Liposarcoma|Non-small Cell Lung Cancer (NSCLC)|Endometrial|Solid Tumors
Interventions: DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant|DRUG: PF-07224826|COMBINATION_PRODUCT: Fulvestrant
Sponsor: Pfizer